Twitter Facebook LinkedIn YouTube

MedReleaf Corp. (TSX: LEAF) New Listing

Video Platform Video Management Video Solutions Video Player

As a licensed producer under the Access to Cannabis for Medical Purposes Regulations, the company is authorized to cultivate and sell cannabis products for medical purposes in both dried and oil form to residents of Canada.

Additional Information:

Company: MedReleaf Corp
Website: http://www.medreleaf.com
Stock Symbol: TSX: LEAF
Date Published: Jun 7, 2017
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

MedReleaf Corp (TSX:LEAF) is the latest new listing on the Toronto Stock Exchange, trading under the symbol “LEAF”.

The company completed an IPO through a syndicate of underwriters, including GMP Securities and Clarus Securities, as co-lead underwriters, including Canaccord Genuity, Cowen & Company, Eight Capital and PI Financial.

MedReleaf raised gross proceeds of $80.7 million with certain shareholders raising an additional $20 million, from the sale of a total of 10.6 million shares at $9.50 per share.

The shares are currently trading at $7.30 and with 90.4 million shares outstanding, the company is capitalized at $660 million.

MedReleaf is the first and only ISO 9001 certified cannabis producer in Canada.

As a licensed producer under the Access to Cannabis for Medical Purposes Regulations, the company is authorized to cultivate and sell cannabis products for medical purposes in both dried and oil form to residents of Canada.

The company’s cannabis-based pharmaceutical products can be ingested in a variety of ways, including smoking, vaporizing, and consumption in the form of oil or edibles.

The company currently operates a 55,000 square foot facility in Markham, Ontario, which has approximately 23,500 square feet of dedicated cultivation space organized into 10 cultivation rooms, and approximately 31,500 square feet of support and auxiliary services.

The Markham Facility is currently capable of producing a minimum of 7,000 kilograms annually, with several initiatives underway to increase this capacity further.

As one of only 43 licensed producers in Canada, MedReleaf has captured approximately 19% of the market.

The company has a seed bank comprised of more than 200 different genetic varieties of cannabis and over 15,000 seeds originating from around the world, which it continues to analyze and catalogue for new varieties offering unique cannabinoid profiles and therapeutic effects.

For more information please visit the company’s website www.medreleaf.com or contact Dennis Fong, Investor Relations, at 416-283-9930 or by email at investorrelations@medreleaf.com.

I’m Samantha Deutscher for Investmentpitch Media